Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain training through implanted electrodes aims to quiet Parkinson's tremors

NCT ID NCT05101161

Symptom relief Sponsor: ETH Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing whether people with Parkinson's disease, epilepsy, or essential tremor can use visual neurofeedback to change abnormal brain activity linked to their symptoms. Participants already scheduled for deep brain stimulation surgery use their implanted electrodes to see their own brain signals on a screen and practice adjusting them. The goal is to learn whether this kind of self-control is possible and whether it can ease symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep brain neurofeedback, a behavioural training that shows brain activity on a screen so people can learn to change it
What this could lead to
If it works, people with Parkinson's disease, epilepsy, or essential tremor might one day tune their own brain activity to ease symptoms, possibly with less reliance on medication or electrical stimulation.
What could go wrong
The approach is experimental and tested in a small group. Not everyone can learn to control brain signals, and the benefits may be short-lived or fail to translate into meaningful symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: patients undergoing clinically indicated implantation of a Percept™ PC neurostimulator, age ≥ 18 years as well as planned hospitalisation of ≥ 3 days after operation Exclusion Criteria: minimal prognosticated survival of less than 1 year, reduced state of consciousness (i. e. Glasgow Coma Scale \< 15), inability to communicate (in terms of hearing, seeing, speaking and understanding), other significant concomitant diseases (e. g. cardiovascular disease, infectious disease, isolation), inability to follow procedures, insufficient knowledge of project language, inability to give consent and unlikeliness to follow protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy essential tremor Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy Essential tremor Parkinson disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ETH Zurich

    RECRUITING

    Zurich, Canton of Zurich, 8092, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.